Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects

Leukemia. 1996 May;10(5):896-900; discussion 901-6.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Blotting, Southern
  • DNA, Neoplasm / analysis
  • Fusion Proteins, bcr-abl / analysis
  • Humans
  • Immunologic Factors / therapeutic use
  • In Situ Hybridization, Fluorescence
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Neoplasm Proteins / analysis
  • Neoplasm, Residual
  • Polymerase Chain Reaction

Substances

  • Biomarkers, Tumor
  • DNA, Neoplasm
  • Immunologic Factors
  • Interferon-alpha
  • Neoplasm Proteins
  • Fusion Proteins, bcr-abl